Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors.
about
Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndromeThe RASopathies: developmental syndromes of Ras/MAPK pathway dysregulationRASopathies: unraveling mechanisms with animal modelsThe RASopathiesThe intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathwayConstitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome.Genetic and environmental melanoma models in fishSmall molecule screening in zebrafish: an in vivo approach to identifying new chemical tools and drug leads.Combined zebrafish-yeast chemical-genetic screens reveal gene-copper-nutrition interactions that modulate melanocyte pigmentation.Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafishCardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines.Characterization of two novel small molecules targeting melanocyte development in zebrafish embryogenesis.MEK Inhibitors Reverse cAMP-Mediated Anxiety in ZebrafishRAS and downstream RAF-MEK and PI3K-AKT signaling in neuronal development, function and dysfunctionLong-term dynamics of multisite phosphorylationIn vivo severity ranking of Ras pathway mutations associated with developmental disorders.Genetic pathways in disorders of epidermal differentiation.The promise of zebrafish as a chemical screening tool in cancer therapy.Genetic Code Expansion in Zebrafish Embryos and Its Application to Optical Control of Cell Signaling.Fish in a Dish: Drug Discovery for Hearing HabilitationAdult mice expressing a Braf Q241R mutation on an ICR/CD-1 background exhibit a cardio-facio-cutaneous syndrome phenotype.Retroviral and lentiviral vectors for the induction of immunological tolerance.Noonan syndrome: comparing mutation-positive with mutation-negative dutch patientsInsulin-like growth factor as a novel stimulator for somatolactin secretion and synthesis in carp pituitary cells via activation of MAPK cascades.Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects.Pathogenetics of the RASopathies.Skeletal muscle pathology in Costello and cardio-facio-cutaneous syndromes: developmental consequences of germline Ras/MAPK activation on myogenesis.How activating mutations affect MEK1 regulation and function.Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethality.Dynamics of Posttranslational Modification Systems: Recent Progress and Future Directions.Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy.
P2860
Q24296397-0419A972-C883-478A-AEF6-D6EC3E7D077FQ24655603-BD61A3D5-994E-4D4D-9E2C-5DF7D16B5F9AQ26800379-63A6CA9E-C2A8-49A9-92FA-C91ADEB56760Q27022142-CF160ECA-66D5-466F-98B1-E003C7662B6CQ28512744-92649F3B-083D-4D8F-9107-ECA19CC0630BQ30499131-1C98CB96-9102-4F3E-8436-0C222B509B59Q33895966-C7733D85-2BD2-4914-9608-1840BFE3FA26Q34029188-76FAE0E8-AFA7-45BC-BBC6-38BF66812535Q34123441-4AE78C4C-9166-4903-8CBB-B173C9C7ED9CQ34149419-6FD97E25-2A2E-4726-911A-F31EC8B809BDQ34263083-2F29347D-FA2D-44A4-A32E-BF6E6638C586Q34265280-1475C2E7-8D8B-4DCE-8052-E6DE0C67C7B2Q36215799-ED6E76D7-8096-4A65-BC56-34F9084F02D2Q36580617-C71ED61D-1DD4-42DF-872C-19251141A296Q37095279-AA341D45-B22F-405F-9355-50C8C85A0E13Q37599060-B7403717-2BB4-4A8F-BBD5-3E73B403FF67Q38058973-B0CB39E1-AA77-4147-8AC3-386A6E473E14Q38558371-2639AD47-3991-491E-A152-C53CCEC35BBCQ38705066-AA8FCF9B-8DF3-4EB1-895F-E1DD12228230Q39321667-4EBCE245-90BB-4CE0-B4C1-743639B4FB0CQ40426379-BFA58263-A816-4EB3-8C7B-679AA0C51D26Q41857863-DE511F5D-1389-417D-A4F6-374EB37E8301Q42018513-CD143AF5-E307-42A7-BE8B-724799CB317FQ42493350-3E169B7B-6EAA-4E6B-B057-43D3B9247628Q42736046-7CE08BEB-229C-473A-AD3F-236E69DDC203Q45957290-51D327F0-539C-4714-94B4-0BE431A45839Q46418352-84A0F566-E9E9-4AB6-AC15-BE09113F5835Q47669262-9E741756-73EB-4963-8EA1-37EC5BEABEE6Q47742602-B7CF0E70-5B11-443E-9A22-A7DC721113ABQ48382418-E6285BF0-930F-4844-B7D5-BF218DE13750Q50134458-30FE56A3-B85D-4FBF-9092-EAEF6E43749AQ50422507-9366F0D2-3FBA-466D-836A-B1FD8FC86243
P2860
Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Kinase-activating and kinase-i ...... to small molecule inhibitors.
@ast
Kinase-activating and kinase-i ...... to small molecule inhibitors.
@en
type
label
Kinase-activating and kinase-i ...... to small molecule inhibitors.
@ast
Kinase-activating and kinase-i ...... to small molecule inhibitors.
@en
prefLabel
Kinase-activating and kinase-i ...... to small molecule inhibitors.
@ast
Kinase-activating and kinase-i ...... to small molecule inhibitors.
@en
P2093
P2860
P356
P1476
Kinase-activating and kinase-i ...... to small molecule inhibitors.
@en
P2093
Anne L Estep
Corina Anastasaki
E Elizabeth Patton
Katherine A Rauen
P2860
P304
P356
10.1093/HMG/DDP186
P577
2009-04-17T00:00:00Z